Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF) (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 22.06% year-over-year to $6.4 million, compared with a TTM value of $25.1 million through Dec 2025, up 28.19%, and an annual FY2025 reading of $23.9 million, up 28.68% over the prior year.
  • Depreciation & Amortization (CF) was $6.4 million for Q4 2025 at Arrowhead Pharmaceuticals, roughly flat from $6.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $6.4 million in Q4 2025 and bottomed at $1.9 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.9 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) grew 2.89% in 2023, then skyrocketed 69.54% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $2.6 million in 2021, then grew by 4.51% to $2.7 million in 2022, then soared by 58.53% to $4.3 million in 2023, then rose by 22.8% to $5.2 million in 2024, then rose by 22.06% to $6.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ARWR at $6.4 million in Q4 2025, $6.4 million in Q3 2025, and $6.2 million in Q2 2025.